(Q48299030)

10 February 2018

title

The amphetamine-like reinforcing effect and mechanism of L-deprenyl on conditioned place preference in mice (English)

1 reference

10 February 2018

author name string

Wu WR

series ordinal

1

1 reference

10 February 2018

Zhu XZ

series ordinal

2

1 reference

10 February 2018

language of work or name

English

0 references

publication date

1 January 1999

1 reference

10 February 2018

European Journal of Pharmacology

published in

1 reference

10 February 2018

volume

364

1 reference

10 February 2018

issue

1

1 reference

10 February 2018

page(s)

1-6

1 reference

10 February 2018

1-methyl-4-phenylpyridinium (MPP+) analogs: in vivo neurotoxicity and inhibition of striatal synaptosomal dopamine uptake

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Ca2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Anatomical disassociation of amphetamine's rewarding and aversive effects: an intracranial microinjection study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Aversive and appetitive properties of anxiogenic and anxiolytic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Pharmacology of selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

1-Methyl-4-phenyl-pyridinium (MPP+) uptake does not explain the differential toxicity of MPP+ in the nigrostriatal and mesolimbic dopaminergic pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Neurotransmitter regulation of dopamine neurons in the ventral tegmental area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self-administration under a progressive ratio schedule of reinforcement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

L-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double blind evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Discrimination of the amphetamine cue. Effects of A, B and mixed type inhibitors of monoamine oxidase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Therapy with l-deprenyl (selegiline) and relation to abuse liability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Place conditioning with dopamine D1 and D2 agonists injected peripherally or into nucleus accumbens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Evaluation of deprenyl for cocaine-like discriminative stimulus effects in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Selegiline as primary treatment in early phase Parkinson's disease--an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2898%2900831-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-2999(98)00831-0

1 reference

10 February 2018

1 reference

10 February 2018